Search results for "antagonist"

showing 10 items of 1660 documents

Brimonidine versus dapiprazole: Influence on pupil size at various illumination levels.

2005

To evaluate the influence of dapiprazole versus brimonidine on pupil size at various illumination levels.Department of Ophthalmology, Johannes Gutenberg-University, Mainz, Germany.In randomized prospective study, 19 healthy volunteers received 2 ophthalmic solutions, dapiprazole and brimonidine, 1 in each eye, for intraindividual comparison. Before and after application, pupil diameter was measured using an infrared binocular pupillometer at 3 illumination levels (0.03, 0.82, and 6.4 lux).Only slight pupil dilation was observed under scotopic conditions after application of both agents. After 20 minutes, the median reduction in pupil width was 1.4 mm for brimonidine and 0.9 mm for dapiprazo…

medicine.medical_specialtygenetic structuresLightmedicine.medical_treatmentDark AdaptationDiagnostic Techniques OphthalmologicalPupilPiperazinesBrimonidine TartrateDapiprazoleRefractive surgeryOphthalmologyQuinoxalinesMydriasisPupillary responseMedicineHumansScotopic visionProspective StudiesAdrenergic alpha-Antagonistsbusiness.industryBrimonidinePupilTriazoleseye diseasesSensory SystemsOphthalmologyAnesthesiaBrimonidine TartrateSurgerysense organsmedicine.symptomOphthalmic SolutionsbusinessAdrenergic alpha-Agonistsmedicine.drugJournal of cataract and refractive surgery
researchProduct

Renin-Angiotensin System Blockade and Mortality in Patients With Hypertension and COVID-19 Infection

2020

To determine the effect renin-angiotensin system blockers on the outcome in patients with hypertension and concurrent COVID-19 infection, we searched PubMed, the Cochrane Library, and Google Scholar for relevant articles. Twelve studies with a total of 16,101 patients met the inclusion criteria. The mortality rate among the users of angiotensin converting enzyme inhibitors or angiotensin receptor blockers was 12.15% and in non-users it was 14.56% (risk ratio 0.70, 95% CI [0.53-0.91], P < 0.007). There was no difference in the risk of death between the use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers (risk ratio 1.09, 95% CI [0.90 -1.32]). We conclude tha…

medicine.medical_specialtyhypertensionCoronavirus disease 2019 (COVID-19)PopulationPneumonia ViralAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologyCochrane LibraryGastroenterologyArticleRenin-Angiotensin System03 medical and health sciencesAngiotensin Receptor AntagonistsBetacoronavirus0302 clinical medicineInternal medicineRenin–angiotensin systemmedicineHumansPharmacology (medical)In patient030212 general & internal medicineeducationPandemicsPharmacologyeducation.field_of_studybiologybusiness.industrySARS-CoV-2Mortality rateCOVID-19Angiotensin-converting enzymerenin-angiotensin-aldosterone systemRelative riskbiology.proteinCardiology and Cardiovascular MedicinebusinessCoronavirus InfectionsAngiotensin II Type 1 Receptor BlockersJournal of Cardiovascular Pharmacology and Therapeutics
researchProduct

Leg extension power asymmetry and mobility limitation in healthy older women

2005

Objective To investigate the association of asymmetry in leg extension power (LEP) with walking and standing balance. Design Cross-sectional analysis. Setting Research laboratory. Participants Healthy female twins (N=419), ages 63 to 75 years. Interventions Not applicable. Main Outcome Measures The LEP difference between the stronger and the weaker leg, measured with the Nottingham power rig, was calculated. Ten-meter maximal walking velocity was assessed in a laboratory corridor on a wide (170cm) and narrow (35cm) track, and the ability to maintain tandem stance for 20 seconds was recorded. Results The mean LEP difference ± standard deviation between the legs was 15%±9% (P<.001). Those wit…

medicine.medical_specialtyliikkumiskykyPower asymmetrymedicine.medical_treatmentMusculoskeletal Physiological PhenomenaeducationTwinsPhysical Therapy Sports Therapy and RehabilitationWalkingSensitivity and SpecificityStandard deviation03 medical and health sciences0302 clinical medicineReference ValuesWalking velocitymedicineHumans030212 general & internal medicineRange of Motion ArticularMuscle SkeletalPostural Balancehealth care economics and organizationsAgedProbabilityAnalysis of VarianceRehabilitationbusiness.industryRehabilitationAge FactorsMiddle AgedBiomechanical PhenomenaStanding balanceCross-Sectional StudiesLower ExtremityMobility LimitationPhysical FitnessMuscle powerPhysical therapyFemaleLeg extensionbusinessalaraajojen voimantuottoteho030217 neurology & neurosurgerypuolierohormones hormone substitutes and hormone antagonists
researchProduct

Therapies in early development for the treatment of opiate addiction.

2015

Opiate drugs are psychoactive substances used to manage severe pain. However, their chronic use is associated with the development of addiction. Opiate addiction represents a significant public health concern.This review focuses on the most recent advances in the pharmacological treatment of opiate addiction, from those being tested in clinical trials (Phase I and II), to preclinical studies that point to new targets. Readers will gain knowledge of the wide variety of treatments used to treat opiate addiction, including their strengths and weaknesses, and the promising pharmacological targets identified by preclinical research.Among the currently available agonist therapies, new dosage form…

medicine.medical_specialtymedia_common.quotation_subjectNarcotic AntagonistsNaltrexonePharmacological treatmentmedicineAnimalsHumansPharmacology (medical)Molecular Targeted TherapyPsychiatrymedia_commonPharmacologybusiness.industryAddictionGeneral MedicineOpioid-Related DisordersNaltrexoneBuprenorphineClinical trialAnalgesics OpioidDrug DesignOpiate addictionOpiatebusinessmedicine.drugMethadoneBuprenorphineExpert opinion on investigational drugs
researchProduct

The early response of the postmenopausal endometrium to tamoxifen: expression of estrogen receptors, progesterone receptors, and Ki-67 antigen

2003

OBJECTIVE To enlighten the early response of endometrium to tamoxifen by assessing the expression of estrogen receptors, progesterone receptors, Ki-67, and the histological response in endometria from normal postmenopausal women treated for 21 days with tamoxifen. DESIGN A total of 40 women, scheduled to undergo vaginal hysterectomy because of uterine prolapse, were randomly assigned to the tamoxifen group (20 mg/day; 20 women) or the control group (20 women). Samples were obtained from the upper and the lower thirds of the uterine cavity. Standard immunohistochemical staining of estrogen and progesterone receptors and of Ki-67 was performed on frozen sections. Staining was assessed using s…

medicine.medical_specialtymedicine.drug_classAdministration OralEstrogen receptorEndometriumEndometriumInternal medicineProgesterone receptormedicineHumansEstrogen receptor betabusiness.industryAntibodies MonoclonalObstetrics and GynecologyMiddle AgedImmunohistochemistryPostmenopauseTamoxifenKi-67 AntigenEndocrinologymedicine.anatomical_structureReceptors EstrogenEstrogenFemaleSimple Endometrial HyperplasiaReceptors ProgesteronebusinessEstrogen receptor alphahormones hormone substitutes and hormone antagonistsTamoxifenmedicine.drugMenopause
researchProduct

Cloning and Functional Characterization of the Ornithokinin Receptor

1997

Kinins are proinflammatory peptides that dilate vessels, increase vascular permeability, contract smooth muscles, and provoke pain. The known mammalian kinin receptors are classified as two subtypes, i.e. the B1 receptor triggered by [des-Arg9]bradykinin and inhibited by [des-Arg9,Leu8]bradykinin, and the B2 receptor stimulated by bradykinin and antagonized by HOE140. Here we report the cloning of a non-mammalian kinin receptor gene amplified from genomic chicken DNA. The protein predicted from the open reading frame shows 31 and 49% sequence identity to the human B1 and B2 receptors, respectively, suggesting that it represents a G protein-coupled receptor of the kinin receptor family. The …

medicine.medical_specialtymedicine.drug_classBradykininCell BiologyBiologyKininReceptor antagonistBiochemistryMolecular biologychemistry.chemical_compoundEndocrinologychemistryInterleukin-21 receptorInternal medicinemedicineEnzyme-linked receptor5-HT5A receptorBradykinin receptorReceptorMolecular BiologyJournal of Biological Chemistry
researchProduct

IL-1β-converting enzyme (caspase-1) in intestinal inflammation

2001

IL-1β-converting enzyme (ICE; caspase-1) is the intracellular protease that cleaves the precursors of IL-1β and IL-18 into active cytokines. In the present study, the effect of ICE deficiency was evaluated during experimental colitis in mice. In acute dextran sulfate sodium-induced colitis, ICE-deficient (ICE KO) mice exhibited a greater than 50% decrease of the clinical scores weight loss, diarrhea, rectal bleeding, and colon length, whereas daily treatment with IL-1 receptor antagonist revealed a modest reduction in colitis severity. To further characterize the function of ICE and its role in intestinal inflammation, chronic colitis was induced over a 30-day time period. During this chron…

medicine.medical_specialtymedicine.drug_classCaspase 1BiologyProinflammatory cytokineMiceAntigens CDInternal medicinemedicineAnimalsColitisMice KnockoutMultidisciplinaryCaspase 1Interleukin-18InterleukinBiological SciencesColitismedicine.diseaseReceptor antagonistEndocrinologyImmunologyInterleukin 18Inflammation MediatorsCell activationIntracellularInterleukin-1Proceedings of the National Academy of Sciences
researchProduct

Treatment of venous thromboembolism – effects of different therapeutic strategies on bleeding and recurrence rates and considerations for future anti…

2012

Abstract Effective treatment of venous thromboembolism (VTE) strikes a balance between prevention of recurrence and bleeding complications. The current standard of care is heparin followed by a vitamin K antagonist such as warfarin. However, this option is not without its limitations, as the anticoagulant effect of warfarin is associated with high inter- and intra-patient variability and patients must be regularly monitored to ensure that anticoagulation is within the narrow target therapeutic range. Several novel oral anticoagulant agents are in the advanced stages of development for VTE treatment, some of which are given after an initial period of heparin treatment, in line with current p…

medicine.medical_specialtymedicine.drug_classDeep veinReviewTherapeutic indexRecurrencemedicinecardiovascular diseasesIntensive care medicinebusiness.industryHeparinlcsh:RC633-647.5AnticoagulantBleedingWarfarinAnticoagulantsHeparinlcsh:Diseases of the blood and blood-forming organsHematologyVitamin K antagonistmedicine.diseaseThrombosisPulmonary embolismSurgerymedicine.anatomical_structureVitamin K antagonistsbusinessmedicine.drugVenous thromboembolismThrombosis Journal
researchProduct

New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension deliver…

2018

COPD causes considerable health and economic burden worldwide, with incidence of the disease expected to continue to rise. Inhaled bronchodilators, such as long-acting muscarinic antagonists (LAMAs) and long-acting β2-agonists (LABAs), are central to the maintenance treatment of patients with COPD. Clinical studies have demonstrated that combined LAMA + LABA therapies improve efficacy while retaining a safety profile similar to LAMA or LABA alone. This has led to the development of several LAMA/LABA fixed-dose combination (FDC) therapies, which provide patients with the convenience of two active compounds in a single inhaler. GFF MDI (Bevespi Aerosphere®) is an FDC of glycopyrrolate/formote…

medicine.medical_specialtymedicine.drug_classDrug CompoundingFixed-dose combinationMuscarinic AntagonistsPulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicineFormoterol FumarateBronchodilatorAdministration InhalationmedicineHumans030212 general & internal medicineIntensive care medicineAdrenergic beta-2 Receptor AgonistsGlycopyrrolateCOPDbiologybusiness.industryInhalerGeneral MedicineLamamedicine.diseasebiology.organism_classificationGlycopyrrolateMetered-dose inhalerBronchodilator AgentsDrug CombinationsTreatment Outcome030228 respiratory systemFormoterolbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee.

2018

OBJECTIVE To determine the current state of knowledge and provide evidence-based recommendations that could be valid for all specialists taking care of female pattern hair loss (FPHL), a common form of hair loss in women that is characterized by the reduction of hair density in the central area of the scalp, whereas the frontal hairline is generally well conserved. PARTICIPANTS An expert task force appointed by the Androgen Excess and PCOS Society, which included specialists from dermatology, endocrinology, and reproductive endocrinology. DESIGN Levels of evidence were assessed and graded from A to D. Peer-reviewed studies evaluating FPHL published through December 2017 were reviewed. Crite…

medicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and MetabolismVasodilator AgentsClinical BiochemistryReproductive EndocrinologySpironolactoneAndrogen ExcessBiochemistry030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineEndocrinology5-alpha Reductase InhibitorsInternal medicinemedicineVitamin D and neurologyHumansLow-Level Light TherapyMineralocorticoid Receptor Antagonists030219 obstetrics & reproductive medicineScalpintegumentary systembusiness.industryPlatelet-Rich PlasmaBiochemistry (medical)HyperandrogenismAlopeciaAndrogen Antagonistsmedicine.diseaseAndrogenDermatologymedicine.anatomical_structureEndocrinologyHair lossMinoxidilScalpMinoxidilFemalebusinessHyperandrogenismmedicine.drugPolycystic Ovary SyndromeThe Journal of clinical endocrinology and metabolism
researchProduct